BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IOTA Pharmaceuticals, KinaseDetect and SARomics Biostructures Announce the Formation of the KINOMED Partnership to Accelerate Human Protein Kinase Drug Discovery


2/22/2011 9:43:35 AM

Cambridge, UK, Odense, Denmark & Lund, Sweden, February 22, 2011 / b3c newswire / - The KINOMED Partnership, funded by the Eurostars program of the European Union, has been established to provide an integrated package of services for protein kinase inhibitor discovery and development. Kinase production, kinase assay development, kinase crystal structure determination, kinase fragment library construction, hit finding and optimisation, in silico screening, kinase biochemical and biophysical screening, structure- and ligand-based drug design and medicinal chemistry services are all included within a single, state-of-the-art offering.

“We are excited to be working with IOTA and KinaseDetect. Both companies are led by world-known researchers with impressive track records within the kinase and kinase drug discovery fields.” says Dr. Derek Logan, CSO of SARomics Biostructures.

Prof. Olaf-Georg Issinger, director of KinaseDetect, comments: “Structure-based drug design in combination with fragment-based lead discovery is a powerful combination in modern drug discovery. We are collaborating with IOTA Pharmaceuticals and SARomics Biostructures in developing a service platform to provide the pharmaceutical industry with off-the-shelf three-dimensional structures of kinases and their complexes with novel lead compounds. The provision of such an integrated service platform will greatly accelerate the drug discovery process for this important class of drugs.” Dr. David Bailey, Director and Co-founder of IOTA, states: “Fragment-based drug discovery at IOTA combines identification of fragments with high ligand efficiency with the power of structure-based drug design, rapidly optimising ligand binding and selectivity in drug-like molecules. The KINOMED Partnership between KinaseDetect, SARomics and IOTA will develop these leads to produce a new generation of kinase therapeutics.”

About IOTA Pharmaceuticals - www.iotapharma.com

IOTA Pharmaceuticals was founded in late 2007 and offers services to the pharmaceutical industry in the emerging area of fragment-based drug discovery. Activities completely span the hit finding and lead optimization stages of drug development, and include target analysis, focused fragment library construction, in silico screening, biochemical and biophysical screening, structure- and ligand-based design and medicinal chemistry services.

About KinaseDetect - www.kinasedetect.dk

KinaseDetect was founded in 2001. Since 2002 recombinant protein kinases are offered to major pharmaceutical companies and to academic customers. Furthermore, kinase assays are offered as service to pharmaceutical companies and a number of projects for different companies have been carried out.

About SARomics Biostructures - www.saromics.com

SARomics Biostructures is the leading Scandinavian provider of structural biology and in silico drug discovery services. The company accelerates its customers’ drug discovery processes by providing contract R&D support in the areas of protein crystallization, X-ray protein structure determination, NMR spectroscopy and computational chemistry. Since its foundation in 2006 the company has successfully carried out a number of projects for companies such as Biovitrum, Active Biotech, LEO Pharma, Inimex Pharmaceuticals and others.

For further general information please visit www.kinomed.com or contact Dr. Björn Walse, Director Sales & Marketing, sales@saromics.com.

To contact KINOMED please use sales@kinomed.com, to obtain further information about current targets and technologies, and to obtain a specific quotation for new structure-led discovery programs.

Contact

Dr. Björn Walse Director Sales & Marketing SARomics Biostructures AB Scheelevägen 22 SE-223 63 Lund sales@saromics.com tel. +46 46 191276



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES